🇩🇰Updated data from Denmark showing highest rates of infection in those who have received *boosters* who are >40 yo
🟢booster
🔵2 doses
🔴previously infected
🟠unvaccinated
But see adjustment for test # s below
Denmark now w/around 85% omicron @SSI_dk (covid19danmark.dk/#gennembrudsin…)
The appearance of negative vax efficacy against infection has been puzzling, especially when separating out prev infected, but @KT_Baek seems to be onto something⬇️ when he adjusts for # of tests taken; this gives v similar infection rates in all 4 groups
Though 2 & 3 doses of vax not effectively preventing infection, 2 doses evidently protecting against severe disease & death in adults & 3 doses seem to offer extra protection in those >70
👇 hospitalization & death rates/100,000 by vax status
🟢booster
🔵2 doses
🟠unvaccinated
Adjusting for test rate may explain the negative vax efficacy seen in Ontario (
), but Denmark is giving us a clear picture of a future where neither 2 nor 3 doses prevents infection.
Can the @CDCgov please make use of @SSI_dk & @KT_Baek 's data & analyses?
indlæggelser= hospitalizations
døde= deaths
Unfortunately there is no data yet being released from @SSI_dk on previous infection's protectiveness against severe disease
• • •
Missing some Tweet in this thread? You can try to
force a refresh
When considering boosters in children:
1 child/78 developed myo in the booster trial among 16-17 yos
& Pfizer's own analysis shows booster would
-prevent 29-69 hospitalizations/mill but would
-result in 23-69 vax myocarditis/mill in males 16-17
🤔Not a great ratio for most boys
And @MartyMakary makes an excellent point here about there not being a VRBPAC expert advisory committee meeting before the FDA authorizes boosters for 12-15 year olds
🇬🇧 The research group at Oxford who compared myocarditis rates after covid to after the vax (nature.com/articles/s4159…) have just released a new analysis:
In males 16-39,
Myocarditis more common after Pfizer dose 2 & 3
&
Moderna dose 2 than after infection medrxiv.org/content/10.110…
I'm already personally aware of 5 cases of post-booster myo in males 16-24; remember, this @NEJM study on boosters by age, the "rate of severe disease in the youngest age groups (16-39) was v low ...not enough cases to estimate the rate ratio reliably" nejm.org/doi/full/10.10…
Current college booster mandates do not seem to have the best interests of the students, especially the male students, at heart. We need better data on the risks and benefits of boosters in the <40 age group.
Danish 🇩🇰 data via @KT_Baek & @SSI_dk
>1/3 of all cases now omicron
No difference in case rates between vax (🔵) & unvax (🟡) in age group w/the most omicron
Prev infection (🔴) still gives some protection
So can we expect vax to protect others? 1/5 covid19danmark.dk/#gennembrudsin…
Based on data above from omicron (no diff in infection risk vax vs unvax) & from delta in @TheLancetInfDis (no significant difference in transm once infected between vax & unvax), it seems:
No, the vax can not be relied on to protect others (2/5)
But, the vaccines still appears effective against severe disease. Here are Danish data on ICU admission by vaccination status
(🟡) unvaccinated
(🔵) 2 or 3 doses
So it appears your vax protects you, not others
(3/5)
I'm being asked to comment on @joerogan's captivating interview of @P_McCulloughMD bc he mentioned our myocarditis study 3 times, 1 here👇. In honor of Dr McCullough saying "the truth is kryptonite" (I love that quote), I wanted to clear up a few things
🧵
1. We found that boys 12-17 w/o medical comorbidities have a risk of myo following vax #2 that exceeds their *120-day* hospitalization risk from covid even at times of high disease prevalence.
The way Dr. McCullough worded it sound like it was overall risk of hospitalization.
2. We identified 257 myocarditis cases in this age group in VAERS up through June 18th, not "thousands". 3. He was spot on about the 86% hospitalization rate
It is hard to understand why decisions like that of Finland (and now Norway) to wait for more safety data before recommending vaccination of 5-11 year olds who aren't high risk would be controversial
The highest rate of post-Pfizer vax myocarditis reported thus far: 1/2700 in 12-17 yo males after vax dose 2.
Considering covid hosp rate after dose 1 or after infection expected to be much lower than this in healthy 12-17 yos, argues against dose 2 for boys (& against mandates)